Preparation and Evaluation of Chitosan Coated PLGA Nanoparticles Encapsulating Ivosidenib with Enhanced Cytotoxicity Against Human Liver Cancer Cells

References

• Man S, Luo C, Yan M, Zhao G, Ma L, Gao W. Treatment for liver cancer: from sorafenib to natural products. Eur J Med Chem. 2021;224:113690. doi:10.1016/j.ejmech.2021.113690
   PubMed Web of Science ®Google Scholar
• Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71(3):616–630. doi:10.1016/j.jhep.2019.06.001
   PubMed Web of Science ®Google Scholar
• Sell S, Leffert HL. Liver cancer stem cells. J Clin Oncol. 2008;26(17):2800–2805. doi:10.1200/JCO.2007.15.5945
   PubMed Web of Science ®Google Scholar
• Dhillon S. Ivosidenib: first global approval. Drugs. 2018;78(14):1509–1516. doi:10.1007/s40265-018-0978-3
   PubMed Web of Science ®Google Scholar
• Norsworthy KJ, Luo L, Hsu V, et al. FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate Dehydrogenase-1 mutation. Clin Cancer Res. 2019;25(11):3205–3209. doi:10.1158/1078-0432.CCR-18-3749
   PubMed Web of Science ®Google Scholar
• Casak SJ, Pradhan S, Fashoyin-Aje L, et al. FDA approval summary: ivosidenib for the treatment of patients with advanced unresectable or metastatic, chemotherapy refractory cholangiocarcinoma with an IDH1 mutation. Clin Cancer Res. 2022;28(13):2733–2737. doi:10.1158/1078-0432.CCR-21-4462
   PubMed Web of Science ®Google Scholar
• Center for drug evaluation and research application number 211192Orig1s000 multi-discipline review. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/211192Orig1s000MultidisciplineR.pdf. Accessed December 17, 2018.
   Google Scholar
• Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. Bioavailability enhancement techniques for poorly aqueous soluble drugs and therapeutics. Biomedicines. 2022;10(9):2055. doi:10.3390/biomedicines10092055
   PubMed Web of Science ®Google Scholar
• Kumari L, Choudhari Y, Patel P, et al. Advancement in solubilization approaches: a step towards bioavailability enhancement of poorly soluble drugs. Life. 2023;13(5):1099. doi:10.3390/life13051099
   Google Scholar
• Tang X, Chen L, Li A, et al. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma. Drug Deliv. 2018;25(1):1484–1494. doi:10.1080/10717544.2018.1477859
   PubMed Web of Science ®Google Scholar
• Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F. Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomed. 2011;6:877–895. doi:10.2147/IJN.S18905
   PubMed Web of Science ®Google Scholar
• Alvi M, Yaqoob A, Rehman K, et al. PLGA-based nanoparticles for the treatment of cancer: current strategies and perspectives. AAPS Open. 2022;8(1):12. doi:10.1186/s41120-022-00060-7
   Google Scholar
• Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011;3(3):1377–1397. doi:10.3390/polym3031377
   PubMed Web of Science ®Google Scholar
• Gentile P, Chiono V, Carmagnola I, Hatton PV. An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int J Mol Sci. 2014;15(3):3640–3659. doi:10.3390/ijms15033640
   PubMed Web of Science ®Google Scholar
• Kapoor DN, Bhatia A, Kaur R, et al. PLGA: a unique polymer for drug delivery. Therap Deliv. 2015;6(1):41–58. doi:10.4155/tde.14.91
   PubMed Web of Science ®Google Scholar
• Alshetaili AS. Gefitinib loaded PLGA and chitosan coated PLGA nanoparticles with magnified cytotoxicity against A549 lung cancer cell lines. Saudi J Biol Sci. 2021;28(9):5065–5073. doi:10.1016/j.sjbs.2021.05.025
   PubMed Web of Science ®Google Scholar
• Mikušová V, Mikuš P. Advances in chitosan-based nanoparticles for drug delivery. Int J Mol Sci. 2021;22(17):9652. doi:10.3390/ijms22179652
   PubMed Web of Science ®Google Scholar
• Abd El Hady WE, Mohamed EA, Soliman OAE, El-Sabbagh HM. In vitro-in vivo evaluation of chitosan-PLGA nanoparticles for potentiated gastric retention and anti-ulcer activity of diosmin. Int J Nanomed. 2019;14:7191–7213. doi:10.2147/IJN.S213836
   PubMed Web of Science ®Google Scholar
• Li T, Ashrafizadeh M, Shang Y, Nuri Ertas Y, Orive G. Chitosan-functionalized bioplatforms and hydrogels in breast cancer: immunotherapy, phototherapy and clinical perspectives. Drug Discov Today. 2024;29(1):103851. doi:10.1016/j.drudis.2023.103851
   Web of Science ®Google Scholar
• Ashrafizadeh M, Hushmandi K, Mirzaei S, et al. Chitosan-based nanoscale systems for doxorubicin delivery: exploring biomedical application in cancer therapy. Bioeng Transl Med. 2022;8(1):e10325. doi:10.1002/btm2.10325
   Web of Science ®Google Scholar
• Ashrafizadeh M, Delfi M, Hashemi F, et al. Biomedical application of chitosan-based nanoscale delivery systems: potential usefulness in siRNA delivery for cancer therapy. Carbohydr Polym. 2021;260:117809. doi:10.1016/j.carbpol.2021.117809
   PubMed Web of Science ®Google Scholar
• Anwer MK, Ali EA, Iqbal M, et al. Development of chitosan-coated PLGA-based nanoparticles for improved oral olaparib delivery: in vitro characterization, and in vivo pharmacokinetic studies. Processes. 2022;10(7):1329. doi:10.3390/pr10071329
   Web of Science ®Google Scholar
• Ahmed MM, Anwer MK, Fatima F, et al. Boosting the anticancer activity of sunitinib malate in breast cancer through lipid polymer hybrid nanoparticles approach. Polymers. 2022;14(12):2459. doi:10.3390/polym14122459
   Web of Science ®Google Scholar
• Fong SS, Foo YY, Saw WS, et al. Chi-tosan-coated-PLGA nanoparticles enhance the antitumor and antimigration activity of stattic – a STAT3 dimerization blocker. Int J Nanomed. 2022;17:137–150. doi:10.2147/IJN.S337093
   PubMed Web of Science ®Google Scholar
• Ritger PL, Peppas NA. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Release. 1987;5(1):37–42. doi:10.1016/0168-3659(87)90035-6
   Google Scholar
• Kalam MA, Iqbal M, Alshememry A, Alkholief M, Alshamsan A. Development and evaluation of chitosan nanoparticles for ocular delivery of tedizolid phosphate. Molecules. 2022;27(7):2326. doi:10.3390/molecules27072326
   PubMed Web of Science ®Google Scholar
• Aljuffali IA, Anwer MK, Ahmed MM, et al. Development of gefitinib-loaded solid lipid nanoparticles for the treatment of breast cancer: physicochemical evaluation, stability, and anticancer activity in breast cancer (MCF-7) cells. Pharmaceuticals. 2023;16(11):1549. doi:10.3390/ph16111549
   Web of Science ®Google Scholar
• Alshetaili AS, Ali R, Qamar W, et al. Preparation, optimization, and characterization of chrysin-loaded TPGS-b-PCL micelles and assessment of their cytotoxic potential in human liver cancer (Hep G2) cell lines. Int J Biol Macromol. 2023;246:125679. doi:10.1016/j.ijbiomac.2023.125679
   Web of Science ®Google Scholar
• Ibrahim S, Baig B, Hisaindee S, et al. Development and evaluation of crocetin-functionalized pegylated magnetite nanoparticles for hepatocellular carcinoma. Molecules. 2023;28(7):2882. doi:10.3390/molecules28072882
   Web of Science ®Google Scholar
• Fu L, Wang S, Wang X, et al. Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer. Sci Rep. 2016;6(1):3. doi:10.1038/s41598-016-0007-2
   Google Scholar
• Devarajan E, Sahin AA, Chen JS, et al. Down-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistance. Oncogene. 2002;21(57):8843–8851. doi:10.1038/sj.onc.1206044
   PubMed Web of Science ®Google Scholar
• Md S, Alhakamy NA, Alharbi WS, et al. Development and evaluation of repurposed etoricoxib loaded nanoemulsion for improving anticancer activities against lung cancer cells. Int J Mol Sci. 2021;22(24):13284. doi:10.3390/ijms222413284
   PubMed Web of Science ®Google Scholar
• Yu W, Liu R, Zhou Y, Gao H. Size-tunable strategies for a tumor targeted drug delivery system. ACS Cent Sci. 2020;6(2):100–116. doi:10.1021/acscentsci.9b01139
   PubMed Web of Science ®Google Scholar
• Bawa R Bio-nanotechnology: a revolution in food, biomedical and health science. Wiley-Blackwell; 2013.
   Google Scholar
• de Oliveira DG, Pimentel GA, Andrade GFS. Chitosan stabilization and control over hot spot formation of gold nanospheres and SERS performance evaluation. Vib Spectrosc. 2020;110:103119. doi:10.1016/j.vibspec.2020.103119
   Web of Science ®Google Scholar
• Phan TTV, Phan DT, Cao XT, et al. Roles of chitosan in green synthesis of metal nanoparticles for biomedical applications. Nanomaterials. 2021;11(2):273. doi:10.3390/nano11020273
   Web of Science ®Google Scholar
• Gu C-H, Sizemore JP, Zhang S Ivosidenib forms and pharmaceutical compositions. US patent No. WO2020010058A1; 2020.
   Google Scholar
• Amjadi I, Rabiee M, Hosseini MS. Anticancer activity of nanoparticles based on PLGA and its co-polymer: in-vitro evaluation. Iran J Pharm Res. 2013;12(4):623–634.
   PubMed Web of Science ®Google Scholar
• Lemoine D, Francois C, Kedzierewicz F, et al. Stability study of nanoparticles of poly (ε-caprolactone), poly (D,L-lactide) and poly(D,L-lactide-co-glycolide). Biomaterials. 1996;17(22):2191–2197. doi:10.1016/0142-9612(96)00049-X
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Ubrich N, Perez H, et al. Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. Int J Pharm. 2000;196(2):177–182. doi:10.1016/S0378-5173(99)00422-6
   Google Scholar
• Malhotra M, Majumdar DK. Permeation through cornea. Indian J Exp Biol. 2001;39:11–24.
   PubMedGoogle Scholar
• Jan R, Chaudhry GE. Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv Pharm Bull. 2019;9(2):205–218. doi:10.15171/apb.2019.024
   PubMed Web of Science ®Google Scholar
• Sun SJ, Deng P, Peng CE, et al. Selenium-modified chitosan induces HepG2 cell apoptosis and differential protein analysis. Cancer Manag Res. 2022;14:3335–3345. doi:10.2147/CMAR.S382546
   PubMed Web of Science ®Google Scholar